Company intelligence / Profile preview
Mithridion
Madison, Wisconsin, United Statesmithridion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mithridion developed oral small-molecule drugs for neurodegenerative diseases, primarily Alzheimer’s disease and schizophrenia. Its lead candidate, MCD‑386CR, completed Phase I trials with potential for improving memory in AD patients and cognition in schizophrenics. The company also explored next-generation compounds and alternative formulations but did not advance beyond early clinical development before becoming inactive.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharma partnerships reported; sought partners for further development post-phase I.
Beyond the preview
Go deeper on Mithridion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mithridion.